Business
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda High absorbed radiation doses, mean
About this update from Plus Therapeutics, Inc.
[{"type":"text","content":"Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to show clinical promise AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data in a podium presentation updating the progress of its ReSPECT-LM clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) in leptomeningeal disease (LM). The data were presented at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, 2024 in Denver, Colorado. The presentation, titled, “Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM): Ongoing Clinical Study Update for Initial Safety and Feasibility,” provided a safety and efficacy update on the single dose trial for the first 4 cohorts (n = 16 patients). The trial is currently enrolling in Cohort 5. The study was presented by Andrew Brenner, M.D., Ph.D., Professor and Kolitz/Zachry Endowed Chair Neuro-Oncology Research; Co-Leader, Experimental and Developmental Therapeutics Program, University of Texas Health, San Antonio. Key ReSPECT-LM highlights through Cohort 4: 16 patients were treated: 8 patients had a breast cancer primary diagnosis, 4 patients had a lung cancer primary diagnosis, and 4 patients had a mix of other primary cancersThere were no dose limiting toxicities through cohort 4 and the maximum tolerated dose or maximum feasible dose was not reachedWe observed a linear increase in absorbed radiation dose to the spinal fluid and ventricles and cranial subarachnoid space over 4 cohortsIn cohort 4, the mean average absorbed radiation dose to the ventricles and cranial subarachnoid space was 156 Gy vs. 1 Gy to the spleenThe majority of adverse events (AEs) across all 4 cohorts were mild or moderate and unrelated or unlikely related to the study drugThere was a mean reduction of CSF circulating tumor cells (CTCs) of 53% at 28 days post treatment vs. baseline ...